Lupin stock
LUPIN.NSNSELupin Limited, HealthcareISIN INE326A01037
76Score 76 out of 100, Strong
Price and trend
44 / 100
Price history
−0.9% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 9.9% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 71).
The price is 20% below its 52-week high. Largest decline in 20 years: 74% (October 2015 to March 2020).
Chart figures for advanced users
- SMA 50$21.57
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$23.76
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)71
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$20.43
- The lowest closing price of the last twelve months.
- Resistance$26.73
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Lupin Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (India) and, with a market value of $9.79B, is number 27 of 77 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $2.97B (up 23.1% year on year) and earnings of $566.82M (up 62.5%).
- For fiscal 2027, analysts expect on average revenue of $3.22B (up 8.3%) and adjusted earnings per share of $1.01 (down 25.3%).
Show more
- MEQIRI Score 76 out of 100 (Strong): rank 52 of 702 in Healthcare, median 53.
- The P/E is 17.8 (Drug Manufacturers (Specialty & Generic) median 32.5, own median of recent years 38.5).
- Our model puts fair value at $28.55, with the price 25% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 34.3% a year since 2021.Growth 93
- High return on capitalReturn on invested capital 28% in fiscal 2026, Drug Manufacturers (Specialty & Generic) median 11.3%.Profitability 83
- Modestly valuedP/E 17.8, Drug Manufacturers (Specialty & Generic) median 32.5, own median 38.5.Valuation 69
Weaknesses
- Margin fallingOperating margin 24.7%, average of the prior years 33.4% (to 2025).
Its standout strengths are growth and stability, while technical analysis holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $20.40 and expensive above $47.59 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $17.92 (cash-flow model) and $39.18 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $27.25, at 11.6% it would be $30.42.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.5).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 24% on the twelve months before. Revenue has grown strongly since 2007, at around 15% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 53%, operating 25%, net 19%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 11 Feb 2027in 90 days
- Last reported
- 3 Nov 2026EPS reported $0.27 (expected $0.26)above expectations
Analyst estimates
Earnings estimates have barely changed since 26 Oct 2026.
- Earnings per share
- $1.01+0.2%
- Revenue
- $3.22B+0.1%
- Earnings per share
- $1.07−1.8%
- Revenue
- $3.43B−0.4%
MEQIRI has stored the estimates since 26 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Lupin
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 76
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- CiplaCIPLA.NS $12.09B67
- Zhejiang NHU002001.SZ $11.75B75
- Mankind PharmaMANKIND.NS $11.58B65
- Aurobindo PharmaAUROPHARMA.NS $11.05B67
- Eisai4523.T $9.14B62
- Shanghai Fosun Pharmaceutical (Group)600196.SS $9.13B47
- H. LundbeckHLUN-B.CO $8.64B80
- Krka, d. d.KRK.WA $8.43B76
ETFs that hold Lupin
Held by 22 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI India UCITS ETFQDV5 | 0.34% | 0.65% | €4.98B |
| iShares Edge MSCI EM Minimum Volatility UCITS ETFEUNZ | 0.29% | 0.40% | €435.04M |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.12% | 0.60% | €31.52M |
Show 5 more
| Amundi MSCI EM Asia ESG Broad Transition UCITS ETF AccLCUA | 0.10% | 0.25% | €661.06M |
| iShares MSCI EM CTB Enhanced ESG UCITS ETFEDM2 | 0.07% | 0.18% | €7.25B |
| iShares MSCI EM Asia UCITS ETFCEBL | 0.06% | 0.20% | €7.14B |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.05% | 0.17% | €5.24B |
| iShares MSCI EM UCITS ETF USD (Acc)EUNM | 0.04% | 0.18% | €9.24B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 3 Oct 2025)
- Valuation signal Fairly valued since 8 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.